Altimmune (ALT) Stock: Buy, Sell, or Hold?
ALT - Altimmune, Inc. Common Stock
$3.24
0.01 (0.31%)
â˛
5d:
-3.28%
30d:
+8.0%
90d:
+23.66%
WAIT
LOW Confidence
Analysis Updated: Sep 16, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When ALT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ALT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ALT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ALT is currently trading at $3.24, which is considered slightly high relative to its 30-day fair value range of $3.00 to $3.29.
Technical Outlook: Technically, ALT is in a strong downtrend. Immediate support is located at $3.10, while resistance sits at $3.55.
Market Sentiment: ALT scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.22 (+431.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ALT is in a strong downtrend. Immediate support is located at $3.10, while resistance sits at $3.55.
Market Sentiment: ALT scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.22 (+431.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.00 -
$3.29
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 431.5% below Wall St target ($17.22)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.00 -
$3.29
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.10
Resistance Level
$3.55
Current Trend
Strong Downtrend
Technical data as of
Sep 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.85
Wall Street Target
$17.22
(+431.5%)
Revenue Growth (YoY)
420.0%
Share & Embed Analysis
Last updated: September 17, 2026 12:43 AM ET
Data refreshes hourly during market hours. Next update: 1:43 AM
Data refreshes hourly during market hours. Next update: 1:43 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 51 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 55 HOLD |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
